Related Experiment Video
Updated: May 13, 2026
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma
Mingqian Feng1, Wei Gao, Ruoqi Wang
1Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD 20892, USA.
Abstract:
Glypican-3 (GPC3) has emerged as a candidate therapeutic target in hepatocellular carcinoma (HCC), but the oncogenic role of GPC3 in HCC is poorly understood. Here, we report a human heavy-chain variable domain antibody, HN3, with high affinity (Kd = 0.6 nM) for cell-surface-associated GPC3 molecules. The human antibody recognized a conformational epitope that requires both the amino and carboxy terminal domains of GPC3. HN3 inhibited proliferation of GPC3-positive cells and exhibited significant inhibition of HCC xenograft tumor growth in nude mice. The underlying mechanism of HN3 action may involve cell-cycle arrest at G1 phase through Yes-associated protein signaling. This study suggests a previously unrecognized mechanism for GPC3-targeted cancer therapy.
Insights
A novel antibody, HN3, targets Glypican-3 (GPC3) in hepatocellular carcinoma (HCC). HN3 inhibits GPC3-positive cell proliferation and HCC tumor growth, suggesting a new therapeutic strategy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Glypican-3 (GPC3) is a potential therapeutic target in hepatocellular carcinoma (HCC).
- The precise oncogenic role of GPC3 in HCC remains incompletely understood.
- Targeting cell-surface molecules offers a promising avenue for cancer therapy.
Purpose of the Study:
- To investigate the therapeutic potential of a novel human antibody, HN3, targeting Glypican-3 (GPC3).
- To elucidate the mechanism of action of HN3 in inhibiting HCC progression.
- To explore a new strategy for GPC3-targeted cancer therapy.
Main Methods:
- Characterization of HN3 antibody affinity and epitope recognition for GPC3.
- In vitro assessment of HN3's effect on GPC3-positive HCC cell proliferation.
- In vivo evaluation of HN3's efficacy in inhibiting HCC xenograft tumor growth in mice.
- Investigation of HN3's mechanism of action, including cell-cycle analysis and signaling pathway assessment (Yes-associated protein).
Main Results:
- HN3 demonstrated high affinity (Kd = 0.6 nM) for cell-surface GPC3.
- HN3 recognized a conformational epitope dependent on GPC3's amino and carboxy terminal domains.
- HN3 significantly inhibited proliferation of GPC3-positive HCC cells.
- HN3 significantly suppressed HCC xenograft tumor growth in vivo.
- HN3-mediated inhibition may involve G1 cell-cycle arrest via Yes-associated protein signaling.
Conclusions:
- HN3 is a potent antibody targeting cell-surface Glypican-3 (GPC3).
- HN3 exhibits significant anti-proliferative and anti-tumor effects against HCC.
- This study reveals a novel mechanism for GPC3-targeted therapy in hepatocellular carcinoma.
